Madrigal Pharmaceuticals (MDGL) Resmetirom Data Likely Leads to Approval in Q4 - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Edward Nash reiterated a Buy rating and $151.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
